Chronic neuroinflammation, a feature common to neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and Amyotrophic Lateral Sclerosis, might be responsive to therapeutic ...

Neurodegenerative diseases are a growing burden worldwide. Common conditions such as Parkinson’s and Alzheimer’s diseases, epileptic encephalopathy and amyotrophic lateral sclerosis (ALS ...

Gaps remain in biomedical research in frontotemporal dementia; however, there are several means by which these gaps can be bridged.

Coya Therapeutics is entering into a phase 2b study for its ALS, and the biotech’s CEO believes it’s on the cusp of a game changer.